Applied Cancer Research

Table 2 Univariate and Multivariate analyses of survival outcomes for MDS patients

From: IL32 expression in peripheral blood CD3⁺ cells from myelodysplastic syndromes patients

Factor	Univariate analysis						Multivariate analysis
	Event free survival			Overall survival			Event free survival			Overall survival
	HR^a	(95% CI)	p	HR^a	(95% CI)	p	HR^a	(95% CI)	p	HR^a	(95% CI)	p
WHO 2008 classification
RAEB-1/RAEB-2 vs. RA/RARS/RCMD	2.73	0.92–8.04	0.07	3.93	1.35–11.47	0.01	8.24	2.20–30.84	0.003	5.58	1.75–17.77	0.003
Gender
Male vs. female	4.74	1.52–14.76	0.007	3.33	1.15–9.64	0.03	9.43	2.57–34.48	0.02	4.17	1.35–12.82	0.01
Age	1.05	1.01–1.09	0.02	1.05	1.01–1.09	0.02	-	-	-	1.06	1.01–1.11	0.03
IL32 expression	1.14	0.98–1.33	0.09	1.08	0.96–1.22	0.23	0.49	0.25–0.94	0.006	-	-	-
IL32α expression	1.08	1.01–1.15	0.02	1.04	0.98–1.09	0.18	3.25	1.69–6.25	0.02	-	-	-
IL32β expression	1.04	0.81–1.32	0.77	1.03	0.85–1.24	0.80	-	-	-	-	-	-
IL32γ expression	1.04	0.96–1.14	0.32	1.03	0.96–1.11	0.42	-	-	-	-	-	-
IL32δ expression	1.04	0.99–1.08	0.06	1.02	0.98–1.05	0.34	0.63	0.47–0.85	0.02	-	-	-

Abbreviations: MDS myelodysplastic syndromes, WHO World Health Organization, HR hazard ratio, CI confidence interval, RA refractory anemia, RARS refractory anemia with ringed sideroblasts, RCMD refractory cytopenia with multilineage dysplasia, RAEB-1 refractory anemia with excess blast-1; RAEB-2, refractory anemia with excess blast-2
Statistically significant p-values are highlighted in bold
^aHazard ratios >1 indicate that the first factor has the poorer outcome. For continuous variables, increase or decrease in the risk is proportional percentage for each one unit increase in the variable

Back to article page